These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

740 related articles for article (PubMed ID: 12601500)

  • 1. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.
    Weiner I
    Psychopharmacology (Berl); 2003 Sep; 169(3-4):257-97. PubMed ID: 12601500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormally persistent latent inhibition induced by lesions to the nucleus accumbens core, basolateral amygdala and orbitofrontal cortex is reversed by clozapine but not by haloperidol.
    Schiller D; Zuckerman L; Weiner I
    J Psychiatr Res; 2006 Mar; 40(2):167-77. PubMed ID: 15882871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs.
    Barak S; Weiner I
    Int J Neuropsychopharmacol; 2009 Mar; 12(2):227-41. PubMed ID: 18687163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment.
    Weiner I; Arad M
    Behav Brain Res; 2009 Dec; 204(2):369-86. PubMed ID: 19433114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol.
    Gaisler-Salomon I; Weiner I
    Psychopharmacology (Berl); 2003 Apr; 166(4):333-42. PubMed ID: 12599023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor.
    Barak S; Weiner I
    Neuropsychopharmacology; 2007 May; 32(5):989-99. PubMed ID: 16971898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latent inhibition in 35-day-old rats is not an "adult" latent inhibition: implications for neurodevelopmental models of schizophrenia.
    Zuckerman L; Rimmerman N; Weiner I
    Psychopharmacology (Berl); 2003 Sep; 169(3-4):298-307. PubMed ID: 12827344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine.
    Barak S; Weiner I
    Psychopharmacology (Berl); 2010 Apr; 209(2):175-84. PubMed ID: 20179909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption and potentiation of latent inhibition by risperidone: the latent inhibition model of atypical antipsychotic action.
    Weiner I; Schiller D; Gaisler-Salomon I
    Neuropsychopharmacology; 2003 Mar; 28(3):499-509. PubMed ID: 12629529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
    Barak S; Weiner I
    Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The switching model of latent inhibition: an update of neural substrates.
    Weiner I; Feldon J
    Behav Brain Res; 1997 Oct; 88(1):11-25. PubMed ID: 9401704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia.
    Barak S; Arad M; De Levie A; Black MD; Griebel G; Weiner I
    Neuropsychopharmacology; 2009 Jun; 34(7):1753-63. PubMed ID: 19158670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluctuation of latent inhibition along the estrous cycle in the rat: modeling the cyclicity of symptoms in schizophrenic women?
    Arad M; Weiner I
    Psychoneuroendocrinology; 2008 Nov; 33(10):1401-10. PubMed ID: 18819755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Latent inhibition is disrupted by nucleus accumbens shell lesion but is abnormally persistent following entire nucleus accumbens lesion: The neural site controlling the expression and disruption of the stimulus preexposure effect.
    Gal G; Schiller D; Weiner I
    Behav Brain Res; 2005 Jul; 162(2):246-55. PubMed ID: 15970218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis?
    Arad M; Weiner I
    Neuropsychopharmacology; 2010 Jun; 35(7):1570-82. PubMed ID: 20237462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered.
    Gaisler-Salomon I; Diamant L; Rubin C; Weiner I
    Psychopharmacology (Berl); 2008 Feb; 196(2):255-67. PubMed ID: 17928997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential involvement of the shell and core subterritories of the nucleus accumbens in latent inhibition and amphetamine-induced activity.
    Weiner I; Gal G; Rawlins JN; Feldon J
    Behav Brain Res; 1996 Nov; 81(1-2):123-33. PubMed ID: 8950008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males.
    Arad M; Weiner I
    Neuropsychopharmacology; 2010 Oct; 35(11):2179-92. PubMed ID: 20613719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacology of latent inhibition as an animal model of schizophrenia.
    Moser PC; Hitchcock JM; Lister S; Moran PM
    Brain Res Brain Res Rev; 2000 Sep; 33(2-3):275-307. PubMed ID: 11011070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Region-specific induction of deltaFosB by repeated administration of typical versus atypical antipsychotic drugs.
    Atkins JB; Chlan-Fourney J; Nye HE; Hiroi N; Carlezon WA; Nestler EJ
    Synapse; 1999 Aug; 33(2):118-28. PubMed ID: 10400890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.